A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

Phase 2 Completed 79 enrolled Zhejiang Doer Biologics Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the efficacy of DR10624 on fasting serum triglyceride (TG) levels after 12 weeks of treatment in subjects with severe hypertriglyceridemia (SHTG).

Timeline

Start: 2024-08-01
Primary completion: 2025-06-30
Completion: 2025-08-29

Outcome

Met primary endpoint

release “在第12周，相较安慰剂，DR10624的所有剂量组的甘油三酯水平均实现显著降低，中位百分比降幅最高达74.5%。” doerbio.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DR10624	Protein / enzyme biologic	—	Subcutaneous

Indications

No indication recorded.